木村 将貴 先生のプロフィール

【受賞】
2006年 第94回日本泌尿器科学会総会賞 受賞
2010年 Josiah Charles Trent Memorial Foundation: Human sexual function grant 受賞
2011年 北米性機能学会Best of Top 10 Basic Science Papers受賞
2015年度 ～ 2017年度 日本学術振興会 科学研究費助成事業若手Ｂ研究「２型糖尿病ラットモデルの勃起機能障害に対する有酸素運動の影響に関する研究」
2015年 GSKジャパン研究助成

【論文】
[1]Kimura M, Nagao K, Tai T, et al. Age is a significant predictor of early and late improvement in semen parameters after microsurgical varicocele repair. Andrologia. in press
[2]Kimura M, Zodda AR, Mahmood J, et al. Pilot Study Evaluating a Rat Model of Radiation-induced Erectile Dysfunction Using an Image-guided Microirradiator. Urology. 2015;85: 1214 e1-6.
[3]Kimura M, Muto S, Horie S. Opportunities for targeted focal treatment in Japan. Curr Opin Urol. 2015;25: 225-9.
[4]Kimura M, Nagao K. Role of varicocele repair for male infertility in the era of assisted reproductive technologies. Reproductive Medicine and Biology. 2014;13: 185-92.
[5]Kimura M, Matsushita T, Nakano M, Iwamoto T. Clinical analysis for factors predicting improvement of semen parameters following subinguinal microsurgical varicocele repair Journal of Fertilization and Implantation. 2014;31: 204-09.
[6]Kimura M, Shimura S, Tai T, et al. A Web-Based Survey of Erection Hardness Score and Its Relationship to Aging, Sexual Behavior, Confidence, and Risk Factors in Japan. Sex Med. 2013;1: 76-86.
[7]Kimura M, Banez LL, Polascik TJ, et al. Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction. Andrology. 2013;1: 256-61.
[8]Kimura M, Shimura S, Kobayashi H, et al. Profiling characteristics of men who use phosphodiesterase type 5 inhibitors based on obtaining patterns: data from the nationwide Japanese population. J Sex Med. 2012;9: 1649-58.
[9]Kimura M, Rabbani ZN, Zodda AR, et al. Role of oxidative stress in a rat model of radiation-induced erectile dysfunction. J Sex Med. 2012;9: 1535-49.
[10]Kimura M, Caso JR, Banez LL, et al. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int. 2012;110: E931-8.
[11]Kimura M, Banez LL, Gerber L, et al. Association between Preoperative Erectile Dysfunction and Prostate Cancer Features-An Analysis from the Duke Prostate Center Database. J Sex Med. 2012;9: 1174-81.
[12]Kimura M, Yan H, Rabbani Z, et al. Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model. J Sex Med. 2011;8: 2215-26.
[13]Kimura M, Donatucci CF, Tsivian M, et al. On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation. Int J Impot Res. 2011;23: 49-55.
[14]Kimura M, Banez LL, Schroeck FR, et al. Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med. 2011;8: 2935-43.
[15]Kimura M, Rabbani Z, Mouraviev V, et al. Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. Cryobiology. 2010;61: 148-54.
[16]Kimura M, Rabbani Z, Mouraviev V, et al. Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology. 2010;76: 764 e14-20.
[17]Kimura M, Mouraviev V, Tsivian M, Moreira DM, Mayes JM, Polascik TJ. Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. Urology. 2010;76: 1258-65.
[18]Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010;105: 191-201.
[19]Kimura M, Baba S, Polascik TJ. Minimally invasive surgery using ablative modalities for the localized renal mass. Int J Urol. 2010;17: 215-27.
[20]Kimura M, Tsivian M, Mouraviev V, et al. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. Int J Urol. 2009;16: 971-5.
[21]Kimura M, Satoh T, Okazaki M, et al. [Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy]. Nippon Hinyokika Gakkai Zasshi. 2008;99: 22-8.
[22]Kimura M, Onozawa M, Fujisaki A, et al. Anti-Ma2 paraneoplastic encephalitis associated with testicular germ cell tumor treated by carboplatin, etoposide and bleomycin. Int J Urol. 2008;15: 942-3.
[23]Kimura M, Irie A, Minei S, et al. [A case of adrenocortical adenoma coexisting with gastrointestinal stromal tumor]. Hinyokika Kiyo. 2007;53: 551-5.
[24] Kimura M, Satoh T, Fujita T, et al. [Cranial nerve palsies due to skull base metastases in patients with prostate cancer: a report of two cases]. Nippon Hinyokika Gakkai Zasshi. 2006;97: 748-51.
[25] Kimura M, Satoh T, Fujita T, et al. [Sudden death after 125I brachytherapy in prostate cancer patient: a case report]. Nippon Hinyokika Gakkai Zasshi. 2005;96: 560-3.